James Boyd

James is an associate lawyer in the class actions department. His practice is focused on class action litigation, including complex product liability and medical class actions. He summered and articled with Siskinds prior to his call to the Bar in 2019.

James received his J.D. from Western University, where he was the recipient of numerous awards including the A.B. Siskind Scholarship for achieving the highest standing in the third year of the J.D. program. He was also part of two national championship-winning oral advocacy teams. He received the First Place Oralist award at the 2017 Willms & Shier Environmental Law Moot from a panel led by Supreme Court of Canada Justice Malcolm Rowe, and he coached Western to victory at the 2018 Warren K. Winkler Class Actions Moot. In recent years he has served as a lecturer at the Faculty of Law and coached teams from Western at various national moots, including at the Class Actions Moot, the Environmental Law Moot, and the Laskin Moot, Canada’s national bilingual moot in administrative and constitutional law.

Prior to pursuing a legal career, James owned and operated a corporate video production company in Toronto for five years, worked in the finance division of Agriculture and Agri-Food Canada, and spent a year teaching English to 6th graders in Kuwait. He is proud parent of two girls.

French

Law Society of British Columbia, Member
Law Society of Ontario, Member
Middlesex Law Association, Member

• “Collateral Benefits: Defending the Causal Rationale” (2018), University of Toronto Faculty of Law Review (76 UT Fac L Rev 92)
• “A Statutory Solution to Ontario’s Environmental Class Action Problem: Section 99(2) of the Environmental Protection Act” (2019), Canadian Class Action Review (14:2 Can Class Action Rev 421)

Western University - Faculty of Law, Lecturer

London Youth Advisory Council, former Board Director

• Ozempic for weight loss? Know the risks of off-label prescriptions
• Bladder drug Elmiron – linked to vision loss, macular degeneration – still among top non-patented drugs in Canada per 2023 report
• Xeljanz, linked to heart attacks, blood clots, and cancers – is now approved to treat arthritis of the spine
• Newly released J&J bankruptcy plan for compensating talcum powder cancer claims includes Canadian claims
• Canadians can now claim under $20 million OxyContin class actions settlement
• Canadian Invokana / Invokamet Settlement now open to claims
• J&J files new bankruptcy case to address talcum powder claims after initial bankruptcy case rejected
• Johnson & Johnson’s bankruptcy strategy for talcum powder cancer lawsuits rejected by US Court
• Group of popular arthritis drugs may pose risk of heart problems, blood clots, cancer and death, says Health Canada
• Johnson & Johnson stopping all sales of talcum-based baby powder
• Arthritis medication Xeljanz linked to risk of heart attack and cancer
• Surgical stapler malfunctions can result in serious injuries
• Conspiracy theory: Is price-matching illegal?
• Class actions as clone wars?
• My data was lost! Can I be compensated?
• Product recalls: Determining if you’re affected and if you have a legal claim
• Product recalls: What recalls mean and where to find information about them
• How many questions is too many on an examination for discovery by written interrogatories?
• Bladder pain medication Elmiron linked to vision loss
• Largest foodborne illness outbreak in years linked to onions contaminated with Salmonella